Catabasis Pharmaceuticals Announces Publication of Phase 1 Clinical Results of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy
-- MoveDMD Trial Data Showed Edasalonexent Was Well-Tolerated with No Safety Signals and Confirmed NF-kB Target Engagement --
“The data from the Phase 1 MoveDMD trial reinforce the good tolerability
and safety profile of edasalonexent that we have now also observed in
the Phase 2 trial and open-label extension,” said
The Phase 1 MoveDMD data demonstrate that:
- Edasalonexent was well tolerated, with all patients completing the 1-week study without serious adverse events or dose reductions and with no safety signals
- Edasalonexent was rapidly absorbed, with peak levels observed 2-6 hours after dosing and exposure was dose-dependent
- After 7 days of treatment, NF-kB-regulated genes were significantly decreased in a dose-dependent manner, confirming that edasalonexent inhibited NF-kB in boys with DMD
“These data support the potential of edasalonexent as a safe and
effective foundational therapy for boys affected by Duchenne. Phase 1
informed dosing for the subsequent MoveDMD trial phases and the
cumulative MoveDMD trial data provided key information to design our
currently enrolling Phase 3 PolarisDMD trial,” said
The primary objective of the Phase 1 portion of the MoveDMD trial was to assess the safety and tolerability of edasalonexent, with the secondary objective to assess the PK and target engagement of edasalonexent in pediatric patients with DMD to provide guidance in the Phase 2 portion of the study. The one week, open-label, multiple-dose study had three ascending doses of edasalonexent (33 mg/kg/day, 67 mg/kg/day and 100 mg/kg/day) administered to males diagnosed with DMD between the ages of 4 and 8 years old.
The results from the MoveDMD trial informed the Phase 3 PolarisDMD trial, which is underway and currently recruiting patients. The PolarisDMD clinical trial is a randomized, double-blind, placebo-controlled trial, with 2 boys receiving edasalonexent for each boy receiving placebo. The PolarisDMD trial is enrolling approximately 125 boys ages 4 to 7 (up to 8th birthday) regardless of mutation type who have not been on steroids for at least 6 months. The MoveDMD and PolarisDMD trials have many important aspects in common including the age range, patient population and key endpoints.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is
an investigational oral small molecule that is being developed as a
potential new standard of care for all patients affected by DMD,
regardless of their underlying mutation. Edasalonexent inhibits NF-kB,
which is a key link between loss of dystrophin and disease progression
in DMD. NF-kB has a fundamental role in skeletal and cardiac muscle
disease in DMD. We are currently enrolling our global Phase 3 PolarisDMD
trial to evaluate the efficacy and safety of edasalonexent for
registration purposes. In our MoveDMD Phase 2 trial and open-label
extension, we observed that edasalonexent preserved muscle function and
substantially slowed disease progression compared to rates of change in
a control period, and significantly improved biomarkers of muscle health
and inflammation. Edasalonexent continues to be dosed in the open-label
extension of the MoveDMD trial. The
About Catabasis
At
Forward Looking Statements
Any statements in this press
release about future expectations, plans and prospects for the Company,
including statements about future clinical trial plans including, among
other things, statements about the Company’s global Phase 3 PolarisDMD
trial in DMD to evaluate the efficacy and safety of edasalonexent for
registration purposes, and other statements containing the words
“believes,” “anticipates,” “plans,” “expects,” “may” and similar
expressions, constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including:
uncertainties inherent in the initiation and completion of preclinical
studies and clinical trials and clinical development of the Company’s
product candidates; whether interim results from a clinical trial will
be predictive of the final results of the trial or the results of future
trials; expectations for regulatory approvals to conduct trials or to
market products; availability of funding sufficient for the Company’s
foreseeable and unforeseeable operating expenses and capital expenditure
requirements; other matters that could affect the availability or
commercial potential of the Company’s product candidates; and general
economic and market conditions and other factors discussed in the “Risk
Factors” section of the Company’s Quarterly Report on Form 10-Q for the
quarter ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20181127005131/en/
Source:
Investor and Media Contact
Andrea
Matthews
Catabasis Pharmaceuticals, Inc.
T: (617) 349-1971
amatthews@catabasis.com